In advance of this month's World Health Assembly and the G7 summit in June, world leaders should consider the establishment of a global biomedical research and development fund and a mechanism to address the dearth in innovation for today's most pressing global health challenges, according to Bernard Pécoul, from the Drugs for Neglected Diseases Initiative, Geneva, Switzerland, and colleagues in an Essay published in this week's PLOS Medicine.

The Essay, which is authored by an international group of leaders of public and private research institutions, non-governmental organizations, and academic groups from Europe, China, India, and South Africa, highlights how a market-led research and development system has failed to deliver innovative new tools to respond to major health challenges, including emerging infectious diseases such as Ebola, anti-microbial resistance, and neglected diseases.

The authors note that while large, international, multi-lateral funds exist for global health delivery, there is no significant pooled funding mechanism for research and development to complement existing but limited R&D funding for a wide range of diseases.

The authors note, "The devastating loss of human life from the Ebola outbreak of 2014 must not be in vain. It must prompt serious changes to our joint international systems for stimulating innovation and ensuring access to health technologies for those who need them."

The authors conclude: "These issues must be on the agenda for the evaluation panels established in the aftermath of Ebola, at the World Health Assembly and UN levels. It must also be a key priority at the G7 summit in June 2015... We call for one of their recommendations to be the establishment of a global biomedical R&D fund and mechanism for innovations of public health importance."

###

Essay

Funding: No funding received for this work.

Competing Interests: The authors have declared that no competing interests exist.

Department of International Cooperation, China National Health and Family Planning Commission, Beijing, People's Republic of China

Drugs for Neglected Diseases initiative, Geneva, Switzerland

Department of Global Health, School of Public Health, Peking University, Peking, China

Swiss Tropical and Public Health Institute, Basel, Switzerland

Norwegian Institute of Public Health, Norway, University of Oslo, Olso, Norway

Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.